| Literature DB >> 35889780 |
Paolo Gentileschi1,2, Leandro Siragusa1,2, Federica Alicata1,2, Michela Campanelli1,2, Chiara Bellantone3, Tania Musca3, Emanuela Bianciardi4, Claudio Arcudi1,2, Domenico Benavoli1,2, Bruno Sensi1,2.
Abstract
INTRODUCTION: Roux-en-Y gastric bypass (RYGB) and one anastomosis gastric bypass (OAGB) are two effective bariatric surgical procedures with positive outcomes in terms of weight loss, comorbidities remission, and adverse events profiles. OAGB seems to carry a higher risk of malnutrition, but existing data are controversial. The aim of this study is to objectively evaluate and compare malnutrition in patients undergoing RYGB and OAGB.Entities:
Keywords: bariatric surgery; gastric bypass; metabolic surgery; nutrition; obesity
Mesh:
Year: 2022 PMID: 35889780 PMCID: PMC9324253 DOI: 10.3390/nu14142823
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
CONUT score.
| Laboratory Parameter | Value | Score |
|---|---|---|
| Total lymphocyte count (mm3) | ||
| >1600 | 0 | |
| 1200–1599 | 1 | |
| 800–1199 | 2 | |
| <800 | 3 | |
| Serum albumin concentration (g/dL) | ||
| ≥3.5 | 0 | |
| 3.0–3.49 | 2 | |
| 2.5–2.99 | 4 | |
| <2.5 | 6 | |
| Serum total cholesterol concentration (mg/dL) | ||
| ≥180 | 0 | |
| 140–179 | 1 | |
| 100–139 | 2 | |
| <100 | 3 |
0–1: normal; 2–4: mild malnutrition; 5–8: moderate malnutrition; 9–12: severe malnutrition.
Diagnostic Criteria for comorbidities.
| Diagnostic Criteria | |
|---|---|
| Hypertension |
▪ 24-h average blood pressure ≥ 130/80 mmHg or ▪ Daytime average blood pressure ≥ 135/85 mmHg or ▪ Night-time average blood pressure ≥ 120/70 mmHg |
| Insulin Resistance Syndrome |
▪ BMI ≥ 25 kg/m2 ▪ Triglyceride level ≥ 150 mg/dL ▪ HDL-C level < 40 mg/dL in men or < 50 mg/dL in women ▪ Blood pressure of ≥ 130/85 mm Hg ▪ Glucose level > 140 mg/dL, 2 h after administration of 75 g of glucose ▪ Fasting glucose level of 110–126 mg/dL |
| Type II Diabetes mellitus |
▪ A 2-h plasma glucose level ≥ 200 mg/dL (11.1 mmol/L) during a 75 g oral glucose tolerance test (OGTT), or ▪ A random plasma glucose ≥ 200 mg/dL (11.1 mmol/L) in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, or ▪ A hemoglobin A1c (HbA1c) level ≥ 6.5% (48 mmol/mol) |
Figure 1The flowchart of study design.
RYGB and OAGB cohort pre-operative characteristics.
| RYGB ( | OAGB ( | ||
|---|---|---|---|
| Sex ( | 0.52 | ||
| Male | 3 (10%) | 8 (17.4%) | |
| Female | 27 (90%) | 40 (83.3%) | |
| Age (Mean, SD) years | 48.5 ± 9.4 | 44.2 ± 13.4 | 0.133 |
| Weight (kg) | 113.9 ± 16.8 | 109.1 ± 14.6 | 0.19 |
| Height (cm) | 164 ± 5.7 | 165 ± 8.5 | 0.576 |
| BMI (kg/m2) | 42.4 ± 7.2 | 40.1 ± 4.6 | 0.09 |
| Comorbidities ( | |||
| Insulin resistance | 8 (26.7%) | 11 (22.9%) | 0.789 |
| Type-2 Diabetes | 6 (20%) | 6 (12.5%) | 0.52 |
| Hypertension | 8 (26.7%) | 21 (43.8%) | 0.154 |
| Cholesterol level (mg/dL) | 210.2 ± 31.2 | 208.2 ± 36.2 | 0.806 |
| Albumin level (gr/dL) | 4.3 ± 0.8 | 3.9 ± 0.8 |
|
| Lymphocytes level (U/mm3) | 2507 ± 615 | 2881 ± 1451 | 0.192 |
| CONUT score | |||
| Mean, SD | 0.48 ± 0.9 | 0.86 ± 1.5 | 0.221 |
| score ≥ 2 ( | 5 (16.6%) | 11 (22.9%) | 0.576 |
BMI: body mass index. Bold: significant results.
Post-operative data at 6-Month Follow-Up: RYGB vs. OAGB.
| RYGB ( | OAGB ( | ||
|---|---|---|---|
| Comorbidities ( | |||
| Insulin resistance | 1 (3.3%) | 1 (2.1%) | 1 |
| Type-2 Diabetes | 2 (6.7%) | 0 (0%) | 0.144 |
| Hypertension | 3 (10%) | 7 (14.5%) | 0.732 |
| Weight (kg) | 84.2 ± 15 | 86.7 ± 17.2 | 0.519 |
| BMI (kg/m2) Mean, SD | 31.2 ± 5.8 | 31.8 ± 5.4 | 0.647 |
| TWL (%) Mean, SD | 26.1 ± 7.2% | 20.5 ± 10.5% | |
| EBMIL (%) Mean, SD | 69.3 ± 23.9% | 56.8 ± 32.7% | |
| Cholesterol level (mg/dL) | 167.6 ± 30.8 | 167.9 ± 37.2 | 0.971 |
| Albumin level (gr/dL) | 4.1 ± 0.5 | 4.3 ± 0.6 | 0.136 |
| Lymphocytes level (U/mm3) | 1891 ± 481 | 2174 ± 1036 | 0.171 |
| CONUT score | |||
| Mean, SD | 1.38 ± 1.5 | 1.45 ± 1.3 | 0.862 |
| score ≥ 2 ( | 11 (36.7%) | 19 (39.6%) | 0.816 |
| score ≥ 9 ( | 0 (0%) | 0 (0%) | - |
BMI: body mass index; TWL: Total Weight Loss; EMBIL: Excess BMI loss.
Pre- vs. post-operative data for RYGB.
| Pre-Operative RYGB ( | Post-Operative RYGB ( | ||
|---|---|---|---|
| Comorbidities ( | |||
| Insulin resistance | 8 (26.7%) | 1 (3.3%) |
|
| Type-2 Diabetes | 6 (20%) | 2 (6.7%) | 0.254 |
| Hypertension | 8 (23.3%) | 3 (10%) | 0.181 |
| Weight (kg) | 113.9 ± 16.8 | 84.2 ± 15 |
|
| BMI (kg/m2) | 42.4 ± 7.2 | 31.2 ± 5.8 |
|
| Cholesterol level (mg/dL) | 210.2 ± 31.2 | 167.6 ± 30.8 |
|
| Albumin level (gr/dL) | 4.3 ± 0.8 | 4.1 ± 0.5 | 0.25 |
| Lymphocytes level (U/mm3) | 2507 ±615 | 1891 ± 481 |
|
| CONUT score | |||
| Mean, SD | 0.48 ±0.9 | 1.38 ± 1.5 |
|
| score ≥ 2 ( | 5 (16.6%) | 11 (36.7%) | 0.153 |
| score ≥ 9 ( | 0 (0%) | 0 (0%) | - |
Bold: significant results.
Pre- vs. post-operative data for OAGB.
| Pre-Operative OAGB ( | Post-Operative OAGB ( | ||
|---|---|---|---|
| Comorbidities ( | |||
| Insulin resistance | 11 (22.9%) | 1 (2.1%) |
|
| Type-2 Diabetes | 6 (12.5%) | 0 (0%) |
|
| Hypertension | 21 (43.8%) | 7 (14.5%) |
|
| Weight (kg) | 109.1 ± 14.6 | 86.7 ± 17.2 | 0.0001 |
| BMI (kg/m2) | 40.1 ± 4.6 | 31.8 ± 5.4 |
|
| Cholesterol level (mg/dL) | 208.2 ± 36.2 | 167.9 ± 37.2 |
|
| Albumin level (gr/dL) | 3.9 ± 0.8 | 4.3 ± 0.6 |
|
| Lymphocytes level (U/mm3) | 2881 ± 1451 | 2174 ± 1036 |
|
| CONUT score | |||
| Mean, SD | 0.86 ± 1.5 | 1.45 ± 1.3 |
|
| score ≥ 2 ( | 11 (22.9%) | 19 (39.6%) | 0.287 |
| score ≥ 9 ( | 0 (0%) | 0 (0%) | - |
Bold: significant results.